Skip to main content
. 2021 May 13;325(23):1–11. doi: 10.1001/jama.2021.7563

Figure 4. Vaccine-Elicited Humoral and Cellular Immune Responses Against SARS-CoV-2 Variants of Concern.

Figure 4.

Serum receptor binding domain (RBD) IgG binding antibody titers and neutralizing antibody titers (NT50) were compared with SARS-CoV-2 wild-type USA-WA1/2020 and variants of concern B.1.1.7 and B.1.351 following 2 doses of vaccines, as well as in cord blood and in breast milk. Peripheral blood mononuclear cells (PBMCs) were stimulated with SARS-CoV-2 wild-type USA-WA1/2020, B.1.1.7, and B.1.351 spike peptides. IFN-γ T-cell responses were measured using enzyme-linked immunospot (ELISPOT) assays and multiparameter intracellular cytokine staining assays gated on total CD4 T cells, CD45RA−CD27+ central memory CD4 T cells, total CD8 T cells, and CD45RA− CD27+ central memory CD8 T cells.

The red bars indicate the median and the dotted lines, the limit of detection. See Table 2 for an explanation of antibody binding and neutralizing assays and ELISPOT and ICS assays.